Analyst Matthew Keller of H.C. Wainwright reiterated a Buy rating on Iterum Therapeutics (ITRM – Research Report), retaining the price target of $9.00.
Confident Investing Starts Here:
- Quickly and easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks straight to you inbox with TipRanks' Smart Value Newsletter
Matthew Keller has given his Buy rating due to a combination of factors that highlight Iterum Therapeutics’ promising future. The company’s lead asset, ORLYNVAH, an orally administered penem antibiotic, has been approved for the treatment of uncomplicated UTIs in women, a significant market given the rising antibiotic resistance. This approval positions Iterum strategically in a market with limited alternative treatments, potentially leading to strong demand for ORLYNVAH.
Furthermore, Iterum’s financial health is bolstered by recent cash inflows, providing a runway for operations into 2026. The company is actively engaging in pre-commercialization activities, such as market research and promotional development, to ensure a successful launch of ORLYNVAH in 4Q25. Additionally, the robust intellectual property protection extending to 2039 further strengthens Iterum’s competitive advantage. These strategic initiatives and financial stability underpin Keller’s confidence in the company’s growth prospects, justifying the Buy rating.
Keller covers the Healthcare sector, focusing on stocks such as FibroGen, Iterum Therapeutics, and GRI Bio. According to TipRanks, Keller has an average return of -26.5% and a 16.67% success rate on recommended stocks.